Evusheld significantly reduced risk of severe COVID-19 or death in TACKLE Phase III treatment trial
Expanding precision medicine, ARTIS icono is designed to enable a wide procedure mix in a single interventional suite
These moves are designed to strengthen the company’s medical and scientific focus and support its continued record growth through closer alignment of all aspects of strategy, sales, and delivery to delight customers
Cytel has now established entities in Australia, Shanghai, Beijing, and Singapore, and plans to expand into Seoul and Tokyo in the coming years.
The company has partnered with Neethi, a Kerala state cooperative consumers federation limited company, to run this program in Kerala
He takes over leadership of Cell & Gene from Jean-Christophe Hyvert, enabling Jean-Christophe to increase his focus on his role as President of the Biologics Division
Results demonstrated a 64.5% confirmed objective response rate in patients treated with investigational combination of enfortumab vedotin and pembrolizumab
In first-line metastatic NSCLC, KEYTRUDA-based regimens have now shown a five-year survival benefit in four trials
Findings to be featured in a late-breaking proffered paper session at European Society for Medical Oncology (ESMO) Congress 2022
Subscribe To Our Newsletter & Stay Updated
